The human T-cell leukemia virus type 1 (HTLV-1), identified as the first human oncogenic
retrovirus 30 years ago, is not an ubiquitous virus. HTLV-1 is present throughout the world …

Human T-cell leukemia virus type 1 (HTLV-1), the first human retrovirus to be discovered, is
present in diverse regions of the world, where its infection is usually neglected in health care …

Findings from the field of evolutionary biology are yielding dramatic insights for health
scientists, especially those involved in the fight against infectious diseases. This book is the …

Human T-lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) is a progressive disease of the CNS that causes weakness or paralysis of the …

Epidemiologic aspects of human T-lymphotropic virus type I (HTLV-I) infection have been
thoroughly studied over the course of approximately 25 years since its first description. The …

The incidence of non-Hodgkin's lymphoma (NHL) has doubled over the past two decades in
the US and most other westernized countries. While improved cancer reporting, changes in …

Human T-cell lymphotropic virus type I (HTLV-I) is the first human retrovirus to be associated
with malignant disease—namely, adult T-cell leukaemia/lymphoma. HTLV-I has also been …

The African continent is considered the largest high endemic area for the oncogenic
retrovirus HTLV-1 with an estimated two to five million infected individuals. However, data on …

The city of Salvador has the highest prevalence of HTLV-I among blood donors in Brazil. To
study the prevalence of HTLV-I among the general population of Salvador, 30 “sentinel …

To evaluate the risk of transfusion‐related transmission of HTLV‐I in Jamaica, a prospective
study was initiated, prior to availability of a licensed HTLV‐I serological screening assay …